Clinical trial
Ambisome® Preemptive Treatment of Multiple Colonizations by Candida in Intensive Care Patients With a Sepsis
NCT00697944 is registered in ClinicalTrials.gov with Fovea as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Ambisome® Preemptive Treatment of Multiple Colonizations by Candida in Intensive Care Patients With a Sepsis
- Lead sponsor
- Fovea
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- March 31, 2008
- Completion date
- March 31, 2009
- Enrollment
- 30 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
candida, sepsis